Chronic Migraine
Conditions
Brief summary
Evaluation of inhibiting rTMS QP over the visual cortex for the prevention of chronic migraine. The aim of the study is to confirm that inhibiting rTMS QP is capable to decrease the frequency of migraine and if its effect is stronger than placebo effect.
Detailed description
The investigators have already inquired if inhibiting rTMS QP over the visual cortex determines a reduction of frequency of migraine in a previous study. After 2 weekly sessions for a month, the investigators demonstrated a reduction of 47% in migraine frequency. In this study, the investigators aim to compare rTMS QP effect with the placebo effect and to evaluate if rTMS QP is capable to induce changes in VEP, CHEPS and QST.
Interventions
DEVICESuper Rapid Magstim Stimulator
The repetitive transcranial magnetic stimulation (rTMS) is able to modify cortical excitability and reactivity. 1Hz rTMS inhibits the cortex, 10Hz excites it. In particular, a new paradigm of rTMS, the rTMS quadri pulse has a more lasting and effective activity. The side effects are rare and transient: migraine,contractions of the muscles of the neck due to muscle stimulation by the electromagnetic field of the coil.
DEVICESuper Rapid Magstim Stimulator (sham)
coil perpendicular to the scalp
Sponsors
University of Liege
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* diagnosis of chronic migraine (ICHD III beta 1.3) with or without medication overuse.
Exclusion criteria
* other diseases or contraindication for the magnetic stimulation (epilepsy, pacemaker, metallic prothesis)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of migraine | 12 months | The investigators evaluate the frequency of migraine during the treatment and 2 months after its end. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Scores on psychological scales | 12 months | The investigators evaluate scores on psychological scales during the treatment and 2 months after its end |
| Intensity of migraine | 12 months | The investigators evaluate the intensity of migraine during the treatment and 2 months after its end |
| Acute medication intake | 12 months | The investigators evaluate acute medication intake during the treatment and 2 months after its end |
| Attack duration | 12 months | The investigators evaluate attack duration during the treatment and 2 months after its end |
Countries
Belgium
Outcome results
None listed